Thymopentin Treatment in Vaginal Mycoses
Author Information
Author(s): Werner Mendling, Ursula Koldovsky
Primary Institution: Wuppental St. Antonius Hospital and Heinrich Heine University, Düsseldorf, Germany
Hypothesis
Can immunologic patient factors be found and treated in women with chronic vaginal candidosis?
Conclusion
Immunologic treatment can reduce the relapse rate of vaginal candidosis in some patients.
Supporting Evidence
- Women with C. albicans vulvovaginitis had fewer T lymphocytes than healthy women.
- Thymopentin treatment led to recovery in women with low T-helper cell counts.
- Immunologic deficiencies were noted in women with chronic vaginal candidosis.
Takeaway
The study looked at women with recurring yeast infections and found that some treatments can help them feel better.
Methodology
The study involved identifying yeast species, quantifying T lymphocytes, and treating patients with thymopentin.
Potential Biases
Potential bias in patient selection and treatment response evaluation.
Limitations
The study had a small sample size and some patients could not be evaluated.
Participant Demographics
42 women with chronic vaginal candidosis, 20 with acute vulvovaginitis, and 14 with C. glabrata vaginitis.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Want to read the original?
Access the complete publication on the publisher's website